Amgen announced that the FDA has approved the administration of KYPROLIS and DARZALEX in combination with dexamethasone to treat patients with recurrent or refractory multiple myeloma. This extended approval of KYPROLIS demonstrates a leap forward in the treatment paradigm of this complex disease by combining two powerful agents.